Ask AI

SignateraTM Ultrasensitive MRD Testing for Head and Neck Cancer Patient Care

Join Dr. Abhinand Peddada, MD and Dr. Michael Krainock MD, PhD as they review the latest clinical data supporting the use of ctDNA for molecular residual disease (MRD) assessment in HNSCC.

Learn how MRD testing has been shown to stratify patients by recurrence risk following curative intent treatment, detect recurrence before radiographic imaging, and predict which patients may benefit from immune checkpoint inhibitor treatment.

The webinar will conclude with a review of real world case studies, practical considerations for implementing MRD testing in routine practice, and future directions for research.

Program Content

Activities

Head and Neck Cancer Patient Care
SignateraTM Ultrasensitive MRD Testing for Head and Neck Cancer Patient Care
Video
Congratulations: You achieved a completion on 04/09/2022

Released: December 16, 2025